Abnormal Intestinal Permeability Predicts Relapse in Inactive Crohn Disease

References

• Sahmound T, Hoctin-Boes G, Modigliani R, Bitoun A, Colombel JF, Soule JC, et al. Identifying patients with a high risk of relapse in quiescent Crohn’s disease. Gut 1995;37:811–8.
   PubMed Web of Science ®Google Scholar
• Steinhardt HJ, Loeschke K, Kasper H, Holtermuller KH, Schafer H. European Cooperative Crohn’s Disease Study (ECCDS): clinical features and natural history. Digestion 1985;31:97–108.
   Google Scholar
• Mekhjian HS, Switz DM, Melnyk CS, Rankin GB, Brooks RK. Clinical features and natural history of Crohn’s disease (NCCDS). Gastroenterology 1979;77:898–906.
   PubMed Web of Science ®Google Scholar
• Andre C, Descos L, Vignal J, Gillon J. C-reactive protein as a predictor of relapse in asymptomatic patients with Crohn’s disease. Scott Med J 1983;28:26–9.
   PubMed Web of Science ®Google Scholar
• Boirivant M, Leoni M, Taricotti D, Fais S, Squarcia O, Pallone F. The clinical significance of serum C reactive protein levels in Crohn’s disease. J Clin Gastroenterol 1988;10:401–5.
   PubMed Web of Science ®Google Scholar
• Wright JP. The differences in acute phase reactants to predict acute relapses of Crohn’s disease [Abstract]. S Afr Med J 1988;73:666.
   Web of Science ®Google Scholar
• Louis E, Belaiche J, Van Kemseke C, Schaaf N, Mahieu P, Mary JY. Soluble interleukin-2 receptor in Crohn’s disease, assessment of disease activity and prediction of relapse. Dig Dis Sci 1994;40:1750–6.
   Web of Science ®Google Scholar
• Brignola C, Campieri M, Bazzocchi G, Farruggia P, Tragnone A, Lanfranchi GA. A laboratory index for predicting relapse in asymptomatic patients with Crohn’s disease. Gastroenterology 1986;91:1490–4.
   PubMed Web of Science ®Google Scholar
• Holloway H, Fielding JF. Colonoscopic findings in Crohn’s disease—reproducible, but of questionable benefit. Can J Gastroenterol 1996;10:405–12.
   PubMed Web of Science ®Google Scholar
• Arnott IDR, Ghosh S, Drummond H, Ferguson A. Crohn’s disease patients in clinical remission show evidence of ongoing mucosal inflammation [Abstract]. Gut 1997;40:A23.
   Web of Science ®Google Scholar
• Soderholm J, Olaison G, Sjodahl R, Tagesson C. Smoking and intestinal absorption of oral polyethylene glycols in Crohn’s disease. Scand J Gastroenterol 1993;28:163–7.
   PubMed Web of Science ®Google Scholar
• Sanderson IR, Boulton P, Menzies I, Walker-Smith JA. Improvement of abnormal lactulose/rhamnose permeability in active Crohn’s disease of the small bowel by an elemental diet. Gut 1987;28:1073–6.
   Google Scholar
• Pironi L, Miglioli M, Ruggeri E, Levorato M, Dallasta MA, Corbelli C, et al. Relationship between intestinal permeability to [51Cr]EDTA and inflammatory activity in asymptomatic patients with Crohn’s disease. Dig Dis Sci 1990;35:582–8.
   PubMed Web of Science ®Google Scholar
• Casellas F, Aguade S, Soriano B, Accarino A, Molero J, Guarner L. Intestinal permeability to 99mTc-diethylenetriaminopenta- acetic acid in inflammatory bowel disease. Am J Gastroenterol 1986;81:767–70.
   PubMed Web of Science ®Google Scholar
• Issenman RM, Jenkins RT, Radoja C. Intestinal permeability compared in pediatric and adult patients with inflammatory bowel disease. Clin Invest Med/Med Clin Exp 1993;16:187–96.
   Google Scholar
• Peeters M, Geypens B, Claus D, Nevens H, Ghoos Y, Verbeke G, et al. Clustering of increased small intestinal permeability in families with Crohn’s disease. Gastroenterology 1997;113:802–7.
   PubMed Web of Science ®Google Scholar
• May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn’s disease? Gastroenterology 1993;104:1627–32.
   Google Scholar
• Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI. Increased intestinal permeability in patients with Crohn’s disease and their relatives. Ann Intern Med 1986;105:883–5.
   PubMed Web of Science ®Google Scholar
• Katz KD, Hollander D, Vadheim CM, McElree C, Delahunty T, Dadufalza VD, et al. Intestinal permeability in patients with Crohn’s disease and their healthy relatives. Gastroenterology 1989;97:927–31.
   PubMed Web of Science ®Google Scholar
• Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995;108:1566–81.
   Google Scholar
• Teahon K, Somasundaram S, Smith T, Menzies I, Bjarnason I. Assessing the site of increased intestinal permeability in coeliac and inflammatory bowel disease. Gut 1996;38:864–9.
   Google Scholar
• Maxton DG, Bjarnason I, Reynolds AP, Catt SD, Peters TJ, Menzies IS. Lactulose, 51Cr EDTA, l-rhamnose and polyethylene glycol 400 as probe markers for ‘in vivo’ assessment of human intestinal permeability. Clin Sci 1986;71:71–80.
   PubMed Web of Science ®Google Scholar
• Ruttenberg D, Young GO, Wright JP, Isaacs S. PEG-400 excretion in patients with Crohn’s disease, their first-degree relatives, and healthy volunteers. Dig Dis Sci 1992;37:705–8.
   PubMed Web of Science ®Google Scholar
• Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn’s disease. Lancet 1993;341:1437–9.
   Google Scholar
• Teahon K, Smethurst P, MacPherson AJ, Levi J, Menzies IS, Bjarnason I. Intestinal permeability in Crohn’s disease and its relation to disease activity and relapse following treatment with elemental diet. Eur J Gastroenterol Hepatol 1993;5:79–84.
   Web of Science ®Google Scholar
• Hilsden RJ, Meddings JB, Hardin J, Gall DG, Sutherland LR. Intestinal permeability and postheparin plasma diamine oxidase activity in the prediction of Crohn’s disease relapse. Inflam Bowel Dis 1999;5:85–91.
   Google Scholar
• Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease index; national cooperative Crohn’s disease study. Gastroenterology 1976;70:439–44.
   PubMed Web of Science ®Google Scholar
• Choudari CP, O’Mahony S, Brydon G, Mwantembe O, Ferguson A. Gut lavage protein concentrations: objective measures of disease activity in inflammatory bowel disease. Gastroenterology 1990;99:1380–7.
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989;24:2–6.
   Web of Science ®Google Scholar
• Bayless TM, Tokayer AZ, Polito JMI, Quaskey SA, Mellits ED, Harris ML. Crohn’s disease: concordance for site and clinical type in affected family members—potential hereditary influences. Gastroenterology 1996;111:573–9.
   PubMed Web of Science ®Google Scholar
• Polito JM, Childs B, Mellits ED, Tokayer AZ, Harris ML, Bayless TM. Crohn’s disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996;111:580–6.
   PubMed Web of Science ®Google Scholar
• Hoffmann RG. Statistics in the practice of medicine. JAMA 1963;185:864–73.
   PubMed Web of Science ®Google Scholar
• Altman DG Practical statistics for medical research. 1st ed. London: Chapman and Hall; 1991. p. 365–94.
   Google Scholar
• Bryman B, Cramer D Quantitative data analysis with minitab: a guide for social scientists. London: Routledge; 1996. p. 218–51.
   Google Scholar
• Bjarnason I, O’Morain C, Levi AJ, Peters TJ. Absorption of 51-chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology 1983;85:318–22.
   PubMed Web of Science ®Google Scholar
• Juby LD, Rothwell J, Axon AT. Lactulose/mannitol test: an ideal screen for celiac disease. Gastroenterology 1989;96:79–85.
   Google Scholar
• Cobden I, Hamilton I, Rothwell J, Axon AT. Cellobiose/mannitol test: physiological properties of probe molecules and influence of extraneous factors. Clin Chim Acta 1985;148:53–62.
   PubMed Web of Science ®Google Scholar
• Laker MF, Bull HJ, Menzies IS. Evaluation of mannitol for use as a probe marker of gastrointestinal permeability in man. Eur J Clin Invest 1982;12:485–91.
   Google Scholar
• Kameda H, Abei T, Nasrallah S, Iber FL. Functional and histological injury to intestinal mucosa produced by hypertonicity. Am J Physiol 1968;214:1090–5.
   PubMed Web of Science ®Google Scholar
• Laker MF, Menzies IS. Increase in human intestinal permeability following ingestion of hypertonic solutions. J Physiol 1977;265:881–94.
   PubMed Web of Science ®Google Scholar
• Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for the maintenance therapy of Crohn’s disease: a meta-analysis. Am J Gastroenterol 1994;89:2116–24.
   Google Scholar
• Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloli C, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn’s disease: a metaanalysis. Am J Gastroenterol 1994; 89:692–8.
   PubMed Web of Science ®Google Scholar
• Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465–73.
   PubMed Web of Science ®Google Scholar
• D’Inca R, Varnier M, Mestriner C, Martines D, D’Odorico A, Sturniolo GC. Effect of moderate exercise on Crohn’s disease patients in remission. Ital J Gastroenterol Hepatol 1999;31:205–10.
   PubMed Web of Science ®Google Scholar
• Binder V, Hendriken C, Kreiner S. Prognosis in Crohn’s disease—based on results from a regional patient group from the county of Copenhagen. Gut 1985;26:146–50.
   Google Scholar
• Lennard-Jones JE, Stadler GA. Prognosis after resection of chronic regional ileitis. Gut 1967;8:332–6.
   PubMed Web of Science ®Google Scholar
• Jenkins RT, Jones DB, Goodacre RL, Collins SM, Coates G, Hunt RH, et al. Reversibility of increased intestinal permeability to 51Cr-EDTA in patients with gastrointestinal inflammatory diseases. Am J Gastroenterol 1987;82:1159–64.
   PubMed Web of Science ®Google Scholar
• O’Mahony S, Choudari CP, Barton JR, Walker S, Ferguson A. Gut lavage fluid proteins as markers of activity of inflammatory bowel disease. Scand J Gastroenterol 1991;26:940–4.
   PubMed Web of Science ®Google Scholar
• Croft NM, Marshall TG, Ferguson A. Gut inflammation in children with cystic fibrosis on high-dose enzyme supplements. Lancet 1995;346:1265–7.
   Google Scholar
• Schreiber S, Nikolaus S, Hampe J, Hamling J, Koop I, Grossner B, et al. Tumour necrosis factor α and interleukin 1β in relapse of Crohn’s disease. Lancet 1999;353:459–61.
   PubMed Web of Science ®Google Scholar